When Does CagriSema Wear Off? A Practical Timing Guide

CagriSema at a glance:

• Drug class: Combination amylin analog (cagrilintide) + GLP-1 agonist (semaglutide)
• Manufacturer: Novo Nordisk
• Route: subcutaneous injection (combined formulation)
• Typical frequency: once weekly
• Half-life: approximately 7 days for both components
• Receptor target: amylin and GLP-1 receptors

If you're looking up CagriSema half-life, you probably have a specific question: when can I switch, how long until it clears, what happens if I miss a dose. We answer all three below.

Half-Life Defined

The half-life is the time it takes for the concentration of a drug in the bloodstream to fall by half. It governs how often a drug needs to be dosed to maintain therapeutic levels and how long the drug persists after the last dose.

For CagriSema, the half-life is approximately 7 days for both components. That number explains the once weekly dosing schedule.

Time to Steady State

After starting (or changing) a dose, drug levels reach a new "steady state" after about 5 half-lives.

For CagriSema: with a 5-7 day half-life, steady state at a new dose is reached around 4-5 weeks. That's why dose increases are spaced ~4 weeks apart in the standard titration schedule.

How Long CagriSema Stays in Your System

A common question: "if I stop CagriSema, how long does it stay in my body?"

The standard rule of thumb is that a drug is essentially cleared after 5 half-lives. For CagriSema: that's approximately 35 days. Effects on appetite, glucose, or other targets persist for a similar period before fully resolving.

For incretin agents specifically, the appetite-related effects fade over weeks after stopping.

Practical Implications

A long half-life:

• Allows less frequent dosing (better adherence)
• Smooths out peaks and troughs (often better tolerability)
• Means dose changes take longer to fully express
• Creates a longer "runway" if a dose is missed

A short half-life:

• Requires more frequent dosing
• Produces sharper concentration peaks (and matching side effects)
• Allows faster dose adjustments
• Provides faster clearance if stopped

CagriSema, with its long half-life, falls on the long end of this spectrum.

Half-Life and Missed Doses

If a dose is missed:

• Take the missed dose as soon as you remember if you're well within the dosing interval
• Skip it if you're closer to the next dose
• Never double up

The longer the half-life, the more forgiving the missed-dose window. For CagriSema, the missed-dose window is relatively forgiving.

Half-Life Across the Drug Class

Within the broader class of combination amylin analog (cagrilintide) + glp-1 agonist (semaglutide), half-lives vary significantly. Daily agents (liraglutide) have shorter half-lives; weekly agents (semaglutide, dulaglutide, tirzepatide) have half-lives in the multi-day range. See our comparison pages for direct comparisons.

Bottom Line

If you only remember one thing about CagriSema pharmacokinetics, make it the half-life. Almost every other practical question traces back to it.

Frequently Asked Questions

Related Reading

• CagriSema: The Complete 2026 Guide (Mechanism, Dosing, Cost)
• CagriSema Side Effects in 2026: Real Reports, Real Solutions
• What Results Should You Expect from CagriSema? A Practical Guide
• The Real CagriSema Price Tag in 2026 — With and Without Insurance
• Is Retatrutide Right for You? An Evidence-Based Breakdown
• What Nobody Tells You About Retatrutide Side Effects

Sources

• Le Roux CW et al. Survodutide for the Treatment of Obesity — Phase 2. Lancet 2024;403:888.
• Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM 2022;387:205.
• Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — Phase 2 Trial. NEJM 2023;389:514.

This page is informational only and is not medical advice.